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Background: Hyperthermia has long been used in combination with chemotherapy or radiation therapy for the
treatment of superficial malignancies, in part due to its sensitizing capabilities. Patients who suffer from superficial
recurrences of breast cancer have poor clinical outcomes. Skin metastases may particularly impair the quality of life
due to the physical appearance, odor and bleeding.
Case presentation: A 66-year-old woman underwent mastectomy and axillary lymph node dissection for breast
cancer. Nine years post-operatively, local metastases developed in the left axillary area (measuring 5 cm in
diameter). Initially the tumor did not respond to radiation therapy and chemotherapy. Therefore, we added
hyperthermia combined with them. Eight weeks later, the tumor became nearly flat and the patient noted
improved activity in her daily life.
Conclusion: Hyperthermia may accelerate the antitumor effects of radiation therapy and chemotherapy. This
treatment provides an alternative for unresectable breast cancer skin metastases.
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Hyperthermia has been combined with radiotherapy in
an effort to improve local control, which is essential in
unresectable locally advanced breast cancer (LABC).
Hyperthermia’s ability to affect cells in S phase, inhibit
sub-lethal damage repair, and improve oxygenation
make it an attractive therapy to combine with radiation
and/or chemotherapy in the hopes of synergy [1-5]. The
ultimate goal of the addition of hyperthermia to treat-
ment for LABC is improved tumor kill, which most
often is assessed with the rate of clinical complete re-
sponse/partial response (cCR/pPR), and if the patient
undergoes surgery, pCR. In addition to the inherent bio-
logy of an individual tumor, achieving a CR with ther-
moradiotherapy depends on the size of the tumor, dose
of radiotherapy used, and ability to adequately heat the
tumor, which can be especially challenging with large
burdens of unresectable disease [6].* Correspondence: yamamotd@hirakata.ac.jp
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A 66-year-old woman underwent mastectomy and axil-
lary lymph node dissection for breast cancer. The histo-
pathological findings were papillo-tubular carcinoma
with metastases in two axillary lymph nodes. IHC staining
showed that estrogen receptor (ER) and progestin recep-
tor (PR) were positive, and Human Epidermal Growth
Factor Receptor 2 (HER-2) oncoprotein was negative. As
adjuvant therapy, doxorubicin (60 mg/m2) and cyclophos-
phamide (600 mg/m2) were administered four times and
aromatase inhibitor was prescribed for five years. There
was no post-mastectomy radiotherapy (PMRT). Nine
years post-operatively, local metastases developed in the
left axillary area. Chemotherapy (weekly paclitaxel:
80 mg/m2) and radiotherapy (total 30 Gy) were attempted,
but the lesions continued to enlarge. On examination, a
tumor measuring 5 cm in diameter was found in the left
axillar area (Figure 1A). Therefore, we added hyperther-
mia combined with radiotherapy and chemotherapy.
Hyperthermia was performed using a Thermotron RF-8
capacitive heating device (Yamamoto VINITA Co., Ltd.,
Osaka, Japan at a surface temperature of 38°C to 41°C,
once a week for 50 minutes [6]. The output power rangedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Skin metastasis from breast cancer was found in the
left axillary area. (A) Before hyperthermia. The diameter of the
tumor was 5 cm. Four weeks (B) and eight weeks (C) later, the
tumor showed gradual shrinkage.
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the tumor began to dissolve, then became gradually nec-
rotic (Figure 1B). Along with a reduction of the tumor
size, the foul odor disappeared. Eight weeks later, the
tumor became nearly flat and the response was evaluated
as a complete response (CR), according to the Response
Evaluation Criteria in Solid Tumors Group criteria, andthe patient noted improved activity in her daily life
(Figure 1C).
Discussion
Breast cancer is the most common neoplasm to
metastasize to the skin. Skin metastases impair activities
of daily life due to the physical appearance, odor and
bleeding. In the present study, chemotherapy (weekly
paclitaxel: 80 mg/m2) and radiotherapy (total 30 Gy)
were attempted, but the lesions continued to enlarge.
On examination, a tumor measuring 5 cm in diameter
was found in the left axillar area (Figure 1A). Therefore, we
added hyperthermia combined with the other therapies. In
general, the first-line therapy for lymphadenopathy is
radiotherapy in which the area was irradiated(total 30 Gy).
Thus, we selected hyperthermia, as the radiotherapy (total
30 Gy) was already applied to the area of axillary lym-
phadenopathy. As a result, we succeeded in controlling
these symptoms through the combined application of
chemo-radiation therapy and hyperthermia, which resulted
in a greatly improved quality of life.
Hyperthermia has been investigated in several rando-
mized and non-randomized clinical trials for cancer
therapy [7-11]. Hyperthermia can increase the thera-
peutic ratio by enhancing the permeability of tumor
blood vessels to liposomes. In pre-clinical studies it has
been demonstrated that the rate of liposomal extravasa-
tion is enhanced four- to eight-fold for temperatures in
the target range of this trial [12]. In cats with soft tissue
sarcomas, hyperthermia enhanced radio-labeled liposo-
mal uptake by 4- to 16-fold compared to normothermia
[13]. Hyperthermia also increases oxygen levels within the
tumor, which is critical to the effectiveness of radiation
and chemotherapy [14-17]. In a clinical setting, some
recent studies [18,19] showed that neoadjuvant chemo-
therapy combined with hyperthermia is a feasible and
well-tolerated treatment strategy in breast cancer
patients. In this study [18], 19 of 44 patients were
deemed inoperable at the initial assessment. Fourteen of
these patients had inflammatory disease. Only five
patients were candidates for breast-conserving surgery
(BCS). Eight patients elected to have BCS, although 16
were eligible after reassessment following neoadjuvant
treatment. At surgery, 32 patients (73%) were found to
have axillary lymph node involvement. No patients pro-
gressed during neoadjuvant therapy. A complete patho-
logical response was seen in four patients (9%). The
combined pathological response was 60% (CR: 9%, and
PR: 51%). Therefore, there is a possibility that the
addition of HT to preoperative chemotherapy increases
cCR and pCR rates more so than chemotherapy alone.
In our previous studies, patients with pCR to chemo-
therapy had a favorable prognosis [20,21]. Thus, the
goal of adding hyperthermia to radiotherapy and/or
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fully local control and disease-free survival.
Conclusions
In conclusion, multidisciplinary therapy, such as hyper-
thermia, radiotherapy and chemotherapy, may be a useful
and effective method for the treatment of progressive
breast cancer.
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